US3420853A - 1-amino-4-phenyl-3-buten-2-ols and salts thereof - Google Patents
1-amino-4-phenyl-3-buten-2-ols and salts thereof Download PDFInfo
- Publication number
- US3420853A US3420853A US471434A US47143465A US3420853A US 3420853 A US3420853 A US 3420853A US 471434 A US471434 A US 471434A US 47143465 A US47143465 A US 47143465A US 3420853 A US3420853 A US 3420853A
- Authority
- US
- United States
- Prior art keywords
- ether
- solution
- added
- mol
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003839 salts Chemical class 0.000 title description 23
- UTHAMCDUNPPWGL-UHFFFAOYSA-N 1-amino-4-phenylbut-3-en-2-ol Chemical class NCC(O)C=CC1=CC=CC=C1 UTHAMCDUNPPWGL-UHFFFAOYSA-N 0.000 title description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 386
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 167
- 239000000243 solution Substances 0.000 description 150
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 123
- -1 for example Substances 0.000 description 96
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 86
- 239000000203 mixture Substances 0.000 description 86
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 69
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 59
- 238000002844 melting Methods 0.000 description 51
- 230000008018 melting Effects 0.000 description 51
- 239000000126 substance Substances 0.000 description 50
- 239000011541 reaction mixture Substances 0.000 description 47
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 46
- 150000001875 compounds Chemical class 0.000 description 38
- 238000003756 stirring Methods 0.000 description 36
- 238000001816 cooling Methods 0.000 description 32
- 230000001476 alcoholic effect Effects 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 24
- 229940022682 acetone Drugs 0.000 description 23
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 22
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 22
- 239000004296 sodium metabisulphite Substances 0.000 description 22
- 235000010262 sodium metabisulphite Nutrition 0.000 description 22
- 239000003208 petroleum Substances 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 238000006722 reduction reaction Methods 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 150000004679 hydroxides Chemical class 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 238000001704 evaporation Methods 0.000 description 14
- 239000012259 ether extract Substances 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 229940117916 cinnamic aldehyde Drugs 0.000 description 12
- 239000012279 sodium borohydride Substances 0.000 description 12
- 229910000033 sodium borohydride Inorganic materials 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- 229910052727 yttrium Inorganic materials 0.000 description 12
- 238000009835 boiling Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Substances OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 8
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 7
- 229910010082 LiAlH Inorganic materials 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229960004132 diethyl ether Drugs 0.000 description 7
- 239000012280 lithium aluminium hydride Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 229930194542 Keto Natural products 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229960004592 isopropanol Drugs 0.000 description 6
- 229910052987 metal hydride Inorganic materials 0.000 description 6
- 150000004681 metal hydrides Chemical class 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 150000003141 primary amines Chemical class 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 150000002118 epoxides Chemical class 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 4
- 238000002211 ultraviolet spectrum Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000219 Sympatholytic Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000002026 chloroform extract Substances 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 2
- DUVJMSPTZMCSTQ-UHFFFAOYSA-N 2-ethoxybenzaldehyde Chemical compound CCOC1=CC=CC=C1C=O DUVJMSPTZMCSTQ-UHFFFAOYSA-N 0.000 description 2
- CTUPBAXICGISQP-UHFFFAOYSA-N 2-methylthiobenzaldehyde Chemical compound CC1=CC=CC=C1C=S CTUPBAXICGISQP-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BWHOZHOGCMHOBV-UHFFFAOYSA-N Benzalacetone Natural products CC(=O)C=CC1=CC=CC=C1 BWHOZHOGCMHOBV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000243621 Vandenboschia maxima Species 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- AKGGYBADQZYZPD-UHFFFAOYSA-N benzylacetone Chemical compound CC(=O)CCC1=CC=CC=C1 AKGGYBADQZYZPD-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000005359 phenoxyalkyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- BWHOZHOGCMHOBV-BQYQJAHWSA-N trans-benzylideneacetone Chemical compound CC(=O)\C=C\C1=CC=CC=C1 BWHOZHOGCMHOBV-BQYQJAHWSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- FJMOXBHYSJFRPZ-VOTSOKGWSA-N (e)-2-hydroxy-4-phenylbut-3-enenitrile Chemical compound N#CC(O)\C=C\C1=CC=CC=C1 FJMOXBHYSJFRPZ-VOTSOKGWSA-N 0.000 description 1
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 1
- HOXFTBYYZGZOQJ-UHFFFAOYSA-N 1-(diethoxymethyl)-2-ethoxybenzene Chemical compound CCOC(OCC)C1=CC=CC=C1OCC HOXFTBYYZGZOQJ-UHFFFAOYSA-N 0.000 description 1
- QWAVNXZAQASOML-UHFFFAOYSA-N 1-phenoxypropan-2-one Chemical compound CC(=O)COC1=CC=CC=C1 QWAVNXZAQASOML-UHFFFAOYSA-N 0.000 description 1
- AFUKNJHPZAVHGQ-UHFFFAOYSA-N 2,5-dimethoxy-Benzaldehyde Chemical compound COC1=CC=C(OC)C(C=O)=C1 AFUKNJHPZAVHGQ-UHFFFAOYSA-N 0.000 description 1
- GHTWMAGYVQDSLS-UHFFFAOYSA-N 2-(diethoxymethyl)-1,3-dimethoxybenzene Chemical compound CCOC(OCC)C1=C(OC)C=CC=C1OC GHTWMAGYVQDSLS-UHFFFAOYSA-N 0.000 description 1
- ITKDNPCXRABQCG-UHFFFAOYSA-N 2-(diethoxymethyl)-1,4-dimethoxybenzene Chemical compound CCOC(OCC)C1=CC(OC)=CC=C1OC ITKDNPCXRABQCG-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- FSMCOBJDZVRWIZ-UHFFFAOYSA-N 2-butoxybenzaldehyde Chemical compound CCCCOC1=CC=CC=C1C=O FSMCOBJDZVRWIZ-UHFFFAOYSA-N 0.000 description 1
- CDUPASLURGOXGD-UHFFFAOYSA-N 2-propoxybenzaldehyde Chemical compound CCCOC1=CC=CC=C1C=O CDUPASLURGOXGD-UHFFFAOYSA-N 0.000 description 1
- WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KKVZAVRSVHUSPL-GQCTYLIASA-N Cassiastearoptene Chemical compound COC1=CC=CC=C1\C=C\C=O KKVZAVRSVHUSPL-GQCTYLIASA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000004705 aldimines Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MFGWMAAZYZSWMY-UHFFFAOYSA-N beta-naphthyl carbinol Natural products C1=CC=CC2=CC(CO)=CC=C21 MFGWMAAZYZSWMY-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057952 methanol Drugs 0.000 description 1
- MKUWVMRNQOOSAT-UHFFFAOYSA-N methylvinylmethanol Natural products CC(O)C=C MKUWVMRNQOOSAT-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- KKVZAVRSVHUSPL-UHFFFAOYSA-N o-methoxycinnamic aldehyde Natural products COC1=CC=CC=C1C=CC=O KKVZAVRSVHUSPL-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-UHFFFAOYSA-N para-methoxycinnamaldehyde Natural products COC1=CC=C(C=CC=O)C=C1 AXCXHFKZHDEKTP-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- LFAGQMCIGQNPJG-UHFFFAOYSA-N silver cyanide Chemical compound [Ag+].N#[C-] LFAGQMCIGQNPJG-UHFFFAOYSA-N 0.000 description 1
- 229940098221 silver cyanide Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/28—Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings
Definitions
- the invention relates to new compounds of Formula I wherein Y and Y are each independently selected from the group consisting of hydrogen, alkyl of l-4 carbon atoms, alkoxy of 1-4 carbon atoms and alkylthio of 1-4 carbon atoms and the pharmaceutically acceptable acid addition salts thereof and to new compounds of the Formula I wherein R is a member selected from the group consisting of alkyl and cycloalkyl, Y and Y are each independently selected from the group consisting of hydrogen, halogen, alkyl of 1-4 carbon atoms, alkoxy of 1-4 carbon atoms and alkylthio of 1-4 carbon atoms and the pharmaceutically acceptable acid addition salts thereof and to new compounds of the Formula 1 wherein R is a member selected from the group consisting of aralkyl and nuclear substituted derivatives thereof Y and Y are each independently selected from the group consisting of hydrogen, halogen, alkyl of l-4 carbon atoms, alkoxy of 1-4 carbon atoms and alkylthi
- the compounds according to the invention have a very significant B-sympatholytic activity. Because of this activity the compounds according to the invention, when brought in a suitable form of administration, may be used in drugs for the treatment arrhythmia and in tachycardia, both in the case that these disturbances of heart regulation are the result of the use of another drug, for example, a uterospasmolytic, and in diseases, for example, angina pectoris and in hypertension. The fall in blood pressure also, as a result of the use of a uterospasmolytic, can be prevented by administering previously one of the compounds according to the invention.
- a uterospasmolytic can be prevented by administering previously one of the compounds according to the invention.
- the fi-sym'patholytic activity of the compounds according to the invention was found in experiments with a preparation of the isolated guinea pig atrium suspended in a Ringer solution and connected to a frequency counter. By the addition of N-isopropylnoradrenaline to this solution a strong frequency increase is produced and the measure in which this effect can be checked was measured by previously administering compounds according to the invention.
- the compound of Formula II Q-CH CH-CHOH-CHa-HN-CHOHa-CHz-Ulla-Q has an activity which lasts many hours longer than that of the known fi-sympatholytic-u-(isopropylaminomethyl)- 2 naphthalene methanol.
- the compound of Formula 11 gave an effect which was found to last over 6 hours.
- the compounds according to the invention can be prepared according to methods which are known for the preparation of analogous compounds and according to methods analogous thereto.
- the compounds according to the invention may be obtained by alkylating, in the reaction of a compound of Formula III, RNH with a compound of Formula IV in which formulae R, Y and Y have the meanings indicated for Formula I, 1*, 1 and I and Z represents one of the groups CHOH-CH Hlg wherein Hlg represents a halogen atom or a hydrate or alcoholate thereof.
- Hlg preferably is Cl, Br or I atom.
- the reaction may be carried out in manners well-known for alkylation reactions, preferably in the presence of an acid binder, for which an excess of the starting amine or, for example, a base, for example, triethylamine or calcium carbonate, may be added and preferably in an inert solvent, for example, an alcohol, for example, methanol or ethanol, a hydrocarbon, for example, benzene or toluene, or an ether, for example, diethyl ether or tetrahydrofurane.
- an acid binder for which an excess of the starting amine or, for example, a base, for example, triethylamine or calcium carbonate, may be added and preferably in an inert solvent, for example, an alcohol, for example, methanol or ethanol, a hydrocarbon, for example, benzene or toluene, or an ether, for example, diethyl ether or te
- the starting halide may be obtained, for example, by reduction of the corresponding keto halide, that is to say, the compound of Formula IV, in which Z represents a group, which reduction may be carried out, for example, by means of a complex metal hydride, for example, NaBH
- a complex metal hydride for example, NaBH
- the epoxide of Formula IV Z is a -C- ⁇ CH2 group
- a base it may consequently be assumed that on alkylation of the compound of formula RNH with the alcohol halide of Formula IV an epoxide of Formula IV is also formed intermediately.
- the epoxide may also be used as the starting material which has been obtained, for example, by treating the alcohol halide of Formula IV with dilute alkali.
- reaction of the epoxide of Formula IV with the compound of formula RNH runs off particularly simply and may be carried out in the presence or in the absence of an inert solvent.
- a Schiif base is intermediately formed which is reduced preferably during the alkylation reaction to the amine of Formula I.
- Z is a keto aldehyde
- the keto group is reduced to a carbinol group.
- a complex metal hydride for example, NaBH is preferably used as a reduction agent.
- the starting substance of Formula IV, in which Z is a group may be obtained, for example, by oxidation of a benzal ace-tone of Formula VI for example, with selenium dioxide, or of a keto halide of Formula VII for example, with dimethylsulphoxide.
- the compound of Formula IV in which is a CHOH-- CHO group may be obtained, for @Xgmple, by reduction 4 of the nitrile of Formula IV, in whch Z is a CHOH-CN group, to the aldimine followed by hydrolysis.
- Another example of a mode of preparing the compounds according to the invention is that in which in a keto compound of Formula VIII the keto group is reduced to a carbinol group.
- this reduction only reduction agents are to be considered which do not reduce the alkene bond.
- reduction agents may be mentioned complex metal hydrides, for example NaBH
- the reduction may be carried out, for example, according to the so-called Meerwein-Pondorf method by means of aluminum isopropylate in isopropanol.
- the amino ketones of Formula VIII may be obtained in different manners.
- a benzal acetone of Formula VI is reacted with isoamylnitrite after which the resulting oxim of Formula IX is converted, by reduction, for example, with stannic chloride, into the primary amino ketone of Formula VIII. If required, this primary amino ketone may be converted into a secondary amine of Formula VIII by alkylation.
- amino ketones of Formula VIII may be obtained by reaction of a com ound of Formula III with a halogen ketone of Formula VII.
- Another example of a method of preparing amino ketones of Formula VIII is that in which an acid chloride of the Formula X is converted with diazomethane into a diazoketone of Formula XI Y1 CHN:
- the primary amine of Formula I may be obtained also, in addition to any of the above methods, by reduction of a compound of formula IV, in which Z represents one of the groups
- the compound of Formula IV, in which Z represents the group CI-I(OH)-CN, the cyanhydrin of a cinnamic aldehyde may be obtained in a simple manner by the addition of HCN to the corresponding cinnamic aldehyde.
- the reduction to the primary amine is preferably carried out by means of a complex metal hydride, in particular with LiAlI-I
- a complex metal hydride in particular with LiAlI-I
- the compounds of Formula IV, in which Z represents a C ON group may be obtained, for example, by replacing in the corresponding cinnamic acid chloride the chlorine atom by the cyano group by means of copper cyanide or silver cyanide or with HCN in pyridine.
- the reduction of the keto cyano compound to the primary amine alcohol of Formula I is preferably carried out by means of a complex metal hydride as a reduction agent. Good results are obtained in particular with LiAlH
- These secondary amines according to the invention may be prepared, for example, by reacting the primary amine of Formula XII with a halide RHlg, in which R represents an alkyl group having 1 to 8 carbon atoms or an aralkyl group or phenoxy alkyl group possibly substituted in the phenyl group by one or two alkyl groups, alkoxy groups or hydroxy groups, and Hlg represents a halogen atom, preferably a chlorine, a bromine or iodine atom.
- RHlg halide
- R represents an alkyl group having 1 to 8 carbon atoms or an aralkyl group or phenoxy alkyl group possibly substituted in the phenyl group by one or two alkyl groups, alkoxy groups or hydroxy groups
- Hlg represents a halogen atom, preferably a chlorine, a bromine or iodine atom.
- salts of the compounds according to the invention are to be considered in particular acid addition salts, for example, those formed from the amine with hydrochloric acid, nitric acid, sulphuric acid, phosphoric acid, sulphamic acid, acetic acid, tartaric acid, citric aid, ascorbic acid, benzoic acid, p.amino benzoic acid, or salicylic acid.
- the new compounds of Formula I 1*, 1, I and their salts are brought, according to methods known per se, into a form of administration suitable for the therapy.
- new pharmaceutical compositions are obtained which are characterized by a content of at least one of the new compounds according to the invention.
- compositions may be mentioned injection liquids, draughts, powders, pills, suppositories, tablets and coated tablets.
- compositions for example, for the preparation of injection liquids solutions in water of salts of the new amines in a concentration of 1-50 mg./ml. are rendered isotonic with blood by means of kitchen salt.
- mixtures of water and alcohols for example, glycerol or benzyl alcohol, may be used as liquid diluents.
- Solid pharmaceutical dosage unit forms are prepared in the normal manner by taking up the active substance in solid pharmaceutical carrier materials, for example, lactose, powdered sugar, potato starch, talcum, magnesium stearate, gum arabic, gelatin, calcium, phosphate and/or titanium dioxide and processing the mixture to tablets or coated tablets.
- solid pharmaceutical carrier materials for example, lactose, powdered sugar, potato starch, talcum, magnesium stearate, gum arabic, gelatin, calcium, phosphate and/or titanium dioxide
- EXAMPLE III 1-methyl-3-phenylpropylamino -4-phenyl-3 -butene-2- ol-HCl To a solution of 2.3 g. (0.0145 mol) of 1-amino-4- phenyl-3-butene-2-ol in 45 ml. of methanol were added 4.5 g. (0.03 mol) of benzylacetone, 5 ml. of 2 N aqueous sodium hydroxide and 2.3 g. of 91% (0.055 mol) of sodium borohydride respectively. The mixture was boiled for two hours, after which the methanol was evaporated in vacuo. 25 ml. of water were added to the residue and the whole was shaken three times with 25 ml.
- EXAMPLE V 1-isopropylamino-4- (4-methoxyphenyl) -3butene-2-olhydrochloride 3.86 g. of the amine obtained according to Example IV and 3.0 ml. of acetone were dissolved in m1. of methanol, after which 0.25 ml. of 2.3 N alcoholic HCl were added. After the mixture had been left to stand at room temperature for 30 minutes, 1.2 g. of approximately 90% NaBH was added and the mixture was then boiled for one hour. After cooling 4 ml. of acetone were added and, after having been left to stand at room temperature again half an hour, 1.6 g. of 90% NaBH; were added and the mixture was boiled for another hour.
- the HCl-solution was made alkaline and extracted with water.
- the ether solution was dried on gMgSO After filtration a solution of 4 g. of oxalic acid in 18 ml. of ethanol was added to the concentrated solution. A precipitate was formed which was washed with ether. Melting point C. (decomposition).
- EXAMPLE VIII l-isopropylamino-4-p-tolyl-3-butene-2-ol hydrochloride (a) 1-amino-4-p-tolyl-3butene-2-ol.-A solution of 49 g. (0.34 mol) of p-methyl cinnamic aldehyde in 50 ml. of ether was stirred for 30 minutes with a solution of 44 g. (0.23 mol) of sodium metabisulphite in 250 ml. of water. 450 ml. of ether were then added and the resulting reaction mixture was cooled while stirring in an ice bath. When the temperature was 5 an ice-cold solution of 41 g.
- EXAMPLE X 4-( 2,6-dimethoxyphenyl)-1-isopropylamino-3-butene-2-0l hydrochloride (a) 2,6 dimethoxybenzaldehyde diethylacetal.This substance was prepared according to the same method as described sub 9a. Yield 92%, boiling point 103-104/ 0.3 mm., melting point 4244 C.
- the mixture was then cooled in an ice bath to 5 and, while stirring, a solution of 31 g. of sodium cyanide in 75 ml. of water which was cooled in ice was added in one portion.
- the mixture was then stirred at 0-5 for 60 minutes, 3.6 g. of sodium metabisulphite were then added and stirring at 05 was continued for another 90 minutes.
- the layers were then separated and the water layer extracted two times with ml. of ether.
- the collected ether extracts were washed twice with 100 ml. of a 20% sodium metabisulphite solution, twice with 100 ml. of water and finally dried on sodium sulphate.
- the Water layer was made alkaline with NaOH 2 N and extracted three times with ether (80 ml.).
- the ether extract was Washed with 20 ml. of water and saturated NaCl-solution and dried on MgSO After filtration the ether was removed in vacuo. The residue was crystallised from a mixture of 20 ml. of benzene and 20 ml. of petroleum ether 40-60. Yield 1.69 g. (59%) melting point 77-78.5 C.
- the temperature was kept below The mixture was stirred for another three hours while cooling with ice after which the layers were separated.
- the water layer was shaken four times with 15 ml. of ether.
- the ether layers were washed two times with water and then dried over Na SO at 0.
- the solution was filtered after which, while cooling with ice, a mixture of 3 m1. of pyridine and 8 ml. of acetic acid anhydride was added dropwise. After leaving to stand the weekend over at 1 room temperature the solution was evaporated to dryness in vacuo 4.57 g. of residue were obtained which were further processed without further purification.
- R is a member selected from the group consisting of alkyl of 1 to 8 carbon atoms inclusive and cyclopentyl
- Y and Y are each independently selected from the group consisting of hydrogen, chlorine, bromine, alkyl of 1-4 carbon atoms, alkoxy of 1-4 carbon atoms and alkylthio of 1-4 carbon atoms and the pharmaceuticaly acceptable acid addition salts thereof.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL6407943A NL6407943A (enrdf_load_stackoverflow) | 1964-07-11 | 1964-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3420853A true US3420853A (en) | 1969-01-07 |
Family
ID=19790501
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US471434A Expired - Lifetime US3420853A (en) | 1964-07-11 | 1965-07-12 | 1-amino-4-phenyl-3-buten-2-ols and salts thereof |
US768925A Expired - Lifetime US3557148A (en) | 1964-07-11 | 1968-10-18 | 1-amino-4-phenyl-3-buten-2-ols and salts thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US768925A Expired - Lifetime US3557148A (en) | 1964-07-11 | 1968-10-18 | 1-amino-4-phenyl-3-buten-2-ols and salts thereof |
Country Status (9)
Country | Link |
---|---|
US (2) | US3420853A (enrdf_load_stackoverflow) |
AT (2) | AT262259B (enrdf_load_stackoverflow) |
BE (1) | BE666781A (enrdf_load_stackoverflow) |
CH (1) | CH470345A (enrdf_load_stackoverflow) |
DE (1) | DE1238898B (enrdf_load_stackoverflow) |
ES (1) | ES315132A1 (enrdf_load_stackoverflow) |
FR (2) | FR1476551A (enrdf_load_stackoverflow) |
GB (1) | GB1117226A (enrdf_load_stackoverflow) |
NL (1) | NL6407943A (enrdf_load_stackoverflow) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4062978A (en) * | 1974-07-04 | 1977-12-13 | Beecham Group Limited | Phenyl butanones |
US4335124A (en) * | 1973-08-20 | 1982-06-15 | Sandoz, Inc. | 1-Alkyl, 1-phenyl-butenes |
US4908481A (en) * | 1980-04-22 | 1990-03-13 | Basf Aktiengesellschaft | Preparation of 1-(4-hydroxy-phenyl)-butan-3-one and novel intermediates |
CN114395379A (zh) * | 2022-01-24 | 2022-04-26 | 西南石油大学 | 一种插层改性纳米碳化钛复合水凝胶封堵剂及水基钻井液 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4080474A (en) * | 1975-02-19 | 1978-03-21 | Beecham Group Limited | Hypolipidaemic compositions |
DE2732750A1 (de) * | 1977-07-20 | 1979-02-08 | Merck Patent Gmbh | Basische thioaether und verfahren zu ihrer herstellung |
FR2473518A1 (fr) * | 1980-01-16 | 1981-07-17 | Unicler | Derives du phenyl-1 morpholino-4 butene-1 ol-3, leur preparation et leur application en therapeutique |
DE10048714A1 (de) * | 2000-09-30 | 2002-04-11 | Gruenenthal Gmbh | 5-Amino-1-penlen-3-ol-Derivate |
-
1964
- 1964-07-11 NL NL6407943A patent/NL6407943A/xx unknown
-
1965
- 1965-07-07 DE DEN26997A patent/DE1238898B/de active Granted
- 1965-07-08 AT AT620665A patent/AT262259B/de active
- 1965-07-08 AT AT1035666A patent/AT258272B/de active
- 1965-07-08 CH CH956965A patent/CH470345A/de not_active IP Right Cessation
- 1965-07-09 ES ES0315132A patent/ES315132A1/es not_active Expired
- 1965-07-09 GB GB29214/65A patent/GB1117226A/en not_active Expired
- 1965-07-10 FR FR24258A patent/FR1476551A/fr not_active Expired
- 1965-07-12 BE BE666781A patent/BE666781A/xx unknown
- 1965-07-12 US US471434A patent/US3420853A/en not_active Expired - Lifetime
- 1965-10-09 FR FR34380A patent/FR5740M/fr not_active Expired
-
1968
- 1968-10-18 US US768925A patent/US3557148A/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
None * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4335124A (en) * | 1973-08-20 | 1982-06-15 | Sandoz, Inc. | 1-Alkyl, 1-phenyl-butenes |
US4062978A (en) * | 1974-07-04 | 1977-12-13 | Beecham Group Limited | Phenyl butanones |
US4908481A (en) * | 1980-04-22 | 1990-03-13 | Basf Aktiengesellschaft | Preparation of 1-(4-hydroxy-phenyl)-butan-3-one and novel intermediates |
CN114395379A (zh) * | 2022-01-24 | 2022-04-26 | 西南石油大学 | 一种插层改性纳米碳化钛复合水凝胶封堵剂及水基钻井液 |
Also Published As
Publication number | Publication date |
---|---|
NL6407943A (enrdf_load_stackoverflow) | 1966-01-12 |
FR5740M (enrdf_load_stackoverflow) | 1968-01-29 |
AT262259B (de) | 1968-06-10 |
GB1117226A (en) | 1968-06-19 |
ES315132A1 (es) | 1966-03-16 |
DE1238898C2 (enrdf_load_stackoverflow) | 1967-11-23 |
BE666781A (enrdf_load_stackoverflow) | 1966-01-12 |
FR1476551A (fr) | 1967-04-14 |
DE1238898B (de) | 1967-04-20 |
CH470345A (de) | 1969-03-31 |
US3557148A (en) | 1971-01-19 |
AT258272B (de) | 1967-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4070539A (en) | [1-Oxo-2-halo(or hydrogen) indanyloxy]-alkanoic acid | |
US3420853A (en) | 1-amino-4-phenyl-3-buten-2-ols and salts thereof | |
JPS5811850B2 (ja) | 1− オキソ −2,2− ジチカン −5− インダニロキシ ( マタハチオ # アルカノイツクアシド | |
US2886589A (en) | 8-methyl-5-oxyphenyl hexahydroindan compounds | |
US4112236A (en) | Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins | |
US4081476A (en) | 1-Aryl-1-lower alkyl-1-buten-3-ols and ester derivatives | |
US3452081A (en) | Phenoxy substituted 2-alkenoic acids | |
Weisler et al. | The Action of Some Benzyl Halides on Salts of Phenylnitromethane and Phenylnitro-acetonitrile | |
HU201509B (en) | Process for production of medical compositions containing as active substance derivatives of phenol and process for production of the active substance | |
US3836543A (en) | Method of preparing dibenzo(d,g)(1,3)dioxocin acids and salts thereof | |
US3362988A (en) | Alkanoylnaphthyloxy-carboxylic acids | |
US4251543A (en) | 2-(p-Prenylphenyl)propionic acid | |
US4036983A (en) | Ferrocene compounds and pharmaceutical composition for use in treatment of iron deficiency in an animal | |
GB2056446A (en) | Alkoxy-benzofuran carboxylic acids and salts and esters thereof | |
US3210413A (en) | Antihypercholesterolemic agents | |
US3943257A (en) | 4-Alkyl-4-naphthyl butenes | |
Schwender et al. | 3-[. alpha.-(tert-Butylamino) methyl]-5-hydroxy-m-xylene-. alpha.,. alpha.'-diol, a selective bronchodilator | |
US3598867A (en) | Dibenzocyclohepta-triene and-diene derivatives | |
US3347910A (en) | Cycloaliphatic substituted naphthyloxy-alkanoic acids and a method for their preparation | |
US4035406A (en) | 4-alkyl-4-naphthyl-butanes | |
US3598860A (en) | 2 - (4 -(3',4' - diphenylcyclopentyl)-phenoxy) lower aliphatic monocarbocyclic acids and esters thereof | |
Palazzo et al. | A new class of hypocholesteremic agents: arylalkyl hydrogen succinates and glutarates | |
US4035427A (en) | α-T-butyl-p-xylene-α-α'-diols and hypolipidemic compositions containing same | |
CH392483A (fr) | Procédé de préparation de nouveaux esters d'acides 4-halo-3-sulfamoyl-benzoïques | |
JPS6330460A (ja) | 2−イソプロピル−2−フェニル−5−(n−メチル−2−フェニルエチルアミノ)バレロニトリル誘導体 |